Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SPIOMET4HEALTH

Financiado

Cerrado

PCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN TOWARD A TREATMENT GUIDED BY PATHOPHYS...

PCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY Polycystic Ovary Syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. It is the most frequent cause of anovulatory subfertility. Ther... ver más

31/03/2026

FUNDACIO PRIVADA P...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FUNDACIO PRIVADA PER LA RECERCA I LA DOCENCIA... Otras actividades asociativas n.c.o.p. asociacion

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 21 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-01

SC1-BHC-08-2020: New interventions for Non-Communica... Specific Challenge:Non-communicable diseases represent a significant burden on individuals and healt...

I+D

Cerrada hace 5 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

21 Participantes

FUNDACIO PRIVADA PER LA RECE...

1.72M€ | Lider

ARQUIMEA INGENIERIA

435.23K€ | Participante

ASPHALION

223.13K€ | Participante

KU Leuven

249.49K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 61 meses Fecha Inicio: 2021-02-01
Fecha Fin: 2026-03-31

Líder del proyecto

FUNDACIO PRIVADA PER LA RECERCA I LA DOCENCIA... Otras actividades asociativas n.c.o.p. asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Polycystic Ovary Syndrome (PCOS) is the most prevalent, chronic endocrine-metabolic disorder of adolescents and young women (AYAs), affecting 5-10% of AYAs worldwide. It is the most frequent cause of anovulatory subfertility. There is no approved therapy for PCOS. Standard off-label treatment with oral contraceptives reverts neither the underlying pathophysiology nor the associated co-morbidities Pilot studies have generated new insights into the pathophysiology of PCOS, and have thus led to the development of a new approach wherein the PCOS phenotype is reverted without side effects. The novel medication is a fixed, low-dose combination of two insulin sensitisers [Pioglitazone (Pio), Metformin (Met)] and one mixed anti-androgen and anti-mineralocorticoid (Spironolactone (Spi)] within a single tablet: SPIOMET SPIOMET4HEALTH will test, in a multicentre Phase II trial, the additive effects of each SPIOMET component, on top of lifestyle measures in AYAs with PCOS. SPIOMET aims at normalising the ovulation rate and endocrine-metabolic status via the reduction of hepato-visceral fat excess, in an early phase of the disorder. This approach is expected to reduce the risk of morbidity (including subsequent anovulatory subfertility), to improve the quality of life, and to lower the economic burden on European healthcare systems. The consortium clusters the experts from key research groups working on PCOS in AYAs, across Europe. The design of SPIOMET4HEALTH foresees that the patients themselves will be engaged over the entire timespan of the project, and will also contribute to the ultimate study evaluation. The update and validation of PCOS-specific Patient Reported Outcome Measures (PROM) will provide the first large-scale evidence on the psychosocial benefits of the tested treatments. The collective evidence from SPIOMET4HEALTH, once completed with economic modelling, will lead to conclusions that inform sound decision-making about PCOS across European healthcare systems.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores